In the current study, we applied bioinformatics analyses to identify potential biomarkers for AMI patients who were at a high risk of HF progression, and two genes, PRKAR1A and SDCBP, were screened due to their consistent expression changes in the study group and validation group. This evidence concerns the gene PRKAR1A and hydrops fetalis.